Search Thermo Fisher Scientific
About the Oncomine Clinical Research Grant Program
The Oncomine Clinical Research Grant Program supports investigator-initiated studies (IIS) and education projects on molecular profiling in oncology, with the goal to increase high quality molecular profiling and help democratize the future of precision medicine. Proposal reviews are conducted by independent and internationally recognized experts together with Thermo Fisher Scientific medical and scientific leadership. Funding is considered based on scientific merit.
The application process is managed by the Oncomine Clinical Research Grant Office, part of the Medical Affairs team of the Clinical Sequencing Division at Thermo Fisher Scientific. For detailed information about how to apply, including documentation requirements, review process, and decision notification, refer to the Guidelines for Applicants.
Grant applications should be submitted electronically (English only) using the application form below. Proposals should outline the planned activities to be performed within a maximum of 12 months. A budget is required for every grant request and should detail the proposed use of the requested funds. The maximum budget request for each project is set at $200,000.
Apply for the Oncomine Clinical Research Grant Program
Submissions for the Oncomine grant program are now being accepted
Submission period: April 1 to May 2, 2025
Proposals will be accepted through the submission portal during the submission period. Alternatively you may email your proposal to medical.affairs@thermofisher.com.
Grant selection process overview
The evaluation process is performed by a committee of external experts in the field, along with Thermo Fisher Scientific medical and scientific leadership. The committee selects awardees based on the scientific merit of the proposed project.
Step 1: Submission
Submission is done by emailing the application form to medical.affairs@thermofisher.com or by using the online grant management portal.
Step 2: Evaluation
Submissions are confirmed by the grant office via email. Decisions are communicated 6 to 8 weeks after the end of the submission period.
Step 3: Execution
Upon contract signature, the requested support will be granted. The grant office team will continue to support the development of the awarded project. A final report is due to the grant office team within the agreed time frame.
Note: The financial support will be made in accordance with local legislation.
Hear from the awardees
“The Oncomine Grant program gives a chance to those who wouldn’t otherwise have it to be able to work with next-generation sequencing technologies. The funding from the Oncomine Grant program can really help us overcome one of the biggest hurdles for smaller and less funded centers to be able to work with these types of emerging technologies.”
Brandon Sheffield, MD
William Osler Health System, Canada
2020 Oncomine Clinical Research Grant awardee
“Industry funding [like the Oncomine Clinical Research Grant program] is important because it can generate a sort of virtual circle, creating a link between the industry and different academic institutions and hospital research labs, and this link can foster the development and the implementation of new platforms or new assays focused on the unmet clinical needs of the future.”
Elena Guerini Rocco, MD
European Institute of Oncology IRCCS, Italy
2021 Oncomine Clinical Research Grant awardee
“The opportunity the Oncomine Grant has afforded us to work on the analysis of the
T cell repertoire has opened also a number of opportunities for my team to collaborate on larger studies. We are now moving from the analysis that we have done with the Oncomine Grant to a large study at the national level to further evaluate these biomarkers and the T cell repertoire.”
Elin Gray, PhD
Edith Cowan University, Australia
2021 Oncomine Clinical Research Grant awardee
Have questions?
For any questions about the Oncomine Clinical Research Grant Program, please email medical.affairs@thermofisher.com.
For Research Use Only. Not for use in diagnostic procedures.